FBLG
HEALTHCAREFibroBiologics Inc
AI Insight
What's Moving FBLG Today?
No stock-specific AI insight has been generated for FBLG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.75$15.00
$0.75
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-7.02
Dividend Yield—
Dividend / Share—
ROE-755.0%
Profit Margin—
Debt / Equity—
Trading
Volume247K
Avg Volume (10D)—
Shares Outstanding5.2M
FBLG News
22 articles- FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound HealingYahoo Finance·Jun 22, 2026
- FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot UlcersYahoo Finance·Jun 16, 2026
- FBLG: Phase 1/2 Trial of CYWC628 UnderwayYahoo Finance·Jun 4, 2026
- FibroBiologics begins dosing patients in diabetic ulcer trial By Investing.comInvesting.com Canada·Jun 3, 2026
- FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot UlcersYahoo Finance·Jun 3, 2026
- EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical TrialYahoo Finance·Jun 3, 2026
- Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?Yahoo Finance·Jun 2, 2026
- FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual MeetingYahoo Finance·May 22, 2026
- FibroBiologics Files Patent Application for Oral Administration of Fibroblast TherapeuticsYahoo Finance·May 18, 2026
- FibroBiologics Advancing Development of a Fibroblast Treatment for HantavirusYahoo Finance·May 11, 2026
- FibroBiologics CEO Issues Letter to ShareholdersYahoo Finance·May 5, 2026
- FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce ScarringYahoo Finance·May 4, 2026
- FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialYahoo Finance·May 4, 2026
- FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate UpdateYahoo Finance·Apr 30, 2026
- FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026Yahoo Finance·Apr 30, 2026
- FibroBiologics Compliant with All Nasdaq Listing RequirementsYahoo Finance·Apr 20, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and ImmunityYahoo Finance·Apr 10, 2026
- FibroBiologics Announces Closing of $3 Million Public OfferingYahoo Finance·Apr 2, 2026
- FBLG: Advancing Fibroblast Therapy on Multiple FrontsYahoo Finance·Apr 1, 2026
- FibroBiologics Announces Pricing of $3 Million Public OfferingGlobeNewswire Inc.·Apr 1, 2026
- FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical TrialYahoo Finance·Mar 31, 2026
All 22 articles loaded
Price Data
Open$0.82
Previous Close$0.81
Day High$0.84
Day Low$0.75
52 Week High$15.00
52 Week Low$0.75
52-Week Range
$0.75$15.00
$0.75
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-7.02
Dividend Yield—
Dividend / Share—
ROE-755.0%
Profit Margin—
Debt / Equity—
Trading
Volume247K
Avg Volume (10D)—
Shares Outstanding5.2M
About FibroBiologics Inc
FibroBiologics, Inc. is a pioneering biotechnology firm focused on advancing regenerative medicine by leveraging fibroblast cell technology to address degenerative diseases and spinal disorders. With a strong intellectual property portfolio, the company is strategically positioned in the dynamic cellular therapy market, emphasizing clinical excellence and innovative treatment solutions. Through strategic partnerships and ongoing research initiatives, FibroBiologics is committed to revolutionizing patient care and improving outcomes with its groundbreaking therapies.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—